A Phase 2 interventional study of Repertaxin and Placebo in Ischemia-Reperfusion Injury and Lung Transplantation, sponsored by Dompé Farmaceutici S.p.A. Completed at 6 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-12-11.
Sponsored by Dompé Farmaceutici S.p.A · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Reperfusion Injury with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Reperfusion Injury · United States.
Among the 44 studies in Reperfusion Injury with a site in United States, this one is the 7th largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2005, is one of 11 in phase 2, and was the 4th registered.
260 studies on the registry are indexed under Reperfusion Injury; 43 are open to participants now.
Browse Reperfusion Injury studies →5 of the 44 studies in Reperfusion Injury with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+
Boston Children's Hospital · Sites in United States
Rhode Island Hospital · Sites in United States
Ages 18–75
Gary Van Guilder · Sites in United States
Ages 18–65 · Healthy volunteers
Mitovation, Inc · Sites in United States
Ages 48 hrs–1 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 28 Reperfusion Injury studies recruiting now, 16 (57%) set no upper age limit and 7 (25%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 18 · Phase 3 7 · Phase 4 1
First in 1997; this study’s year is marked. 2 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 114 is above the median of 60 across 212 interventional studies indexed under Reperfusion Injury.
Median enrollment 30 across the 39 interventional studies, 20 across the 5 observational. Of the 32 that completed or were terminated, 13 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 44 have an industry lead sponsor. The 10 most frequent:
Dompé Farmaceutici S.p.A is the lead sponsor of 52 studies on the registry; 4 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 18 (100%) have results posted.
Dompé Farmaceutici S.p.A has 3 studies filed under Reperfusion Injury — fewer than ten, so there is no comparison to draw.
3 of the studies in Reperfusion Injury with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03663543University of PennsylvaniaIntravenous Estrogen in Kidney Transplant Study | 2027-01-31 |
| NCT05574296Boston Children's HospitalHydrogen's Feasibility and Safety as a Therapy in ECPR | 2027-03-31 |
| NCT07385651Vanderbilt University Medical CenterDeceased Donor Kidney Storage at 10 Celsius Versus Conventional Storage | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 44 studies in Reperfusion Injury with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this clinical study was to evaluate whether CXCL8 (CXC ligand 8 [formerly interleukin (IL)-8]) inhibition with repertaxin leads to reduced severity of primary graft dysfunction, as the result of improved functional and clinical outcomes in lung transplantation patients.
The safety of repertaxin in the specific clinical setting was also evaluated.
The ability of repertaxin to reduce target cells (polymorphonuclear leukocyte [PMN]) infiltration into the graft was evaluated to confirm its mechanism of action.
This was a phase 2, multi-center, randomized, double-blind, placebo-controlled, parallel-group (two arms) study.
A total of 100 patients accepted and listed for lung transplantation, who met all of the study inclusion and none of the exclusion criteria described in Sections 9.3.1 and 9.3.2 of this report, were planned to be enrolled in the study. These patients were randomly assigned in a 1:1 ratio to receive either repertaxin or placebo, by continuous intravenous infusion for a period of 48 hours to start approximately 2 hours before reperfusion of the (first) transplanted lung occurred.
The experimental treatment was additional to the standard treatment of lung transplant recipients.
An initial 'loading dose' of repertaxin of 4.488 mg/kg body weight/hour was to be administered over 30 minutes followed by a maintenance dose of 2.772 mg/kg body weight/hour lasting 47.5 hours.
Placebo was to be volume matched saline. Total infusion volume was not to exceed 500 mL/24 hours. Study medication was to be provided as clear glass class I ampoules, each containing 10 mL of the following products: repertaxin (33 mg/mL aqueous injectable solution) and placebo (9 mg/mL aqueous injectable solution of NaCl).
The double-blind was to be maintained for the main part of the study only, i.e. up to the Month 1 (at least 30 days post-transplant) follow-up visit of the last patient in. After database lock of Month 1 data the study proceeded in an open fashion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Both repertaxin and placebo were aqueous solutions packaged into identical clear glass Type I ampoule single dose units. Each ampoule contained 10 mL of either repertaxin or placebo.The dosing solution for infusion was prepared aseptically at the designated Pharmacy within each center and dispensed as 12.65 mg/mL solution in appropriate size infusion bags. An initial 'loading dose' of Repertaxin of 4.488 mg/kg body weight/hour was administered over 30 minutes followed by a maintenance dose of 2.772 mg/kg body weight/hour lasting 47.5 hours.The loading and maintenance doses were administered using the same dosing solution (Repertaxin 12.65 mg/ml), but with the pump rate altered to provide an infusion rate of approximately 0.35 mUkg/hour and 0.22 ml/kg/hour, respectively.
Drug: Repertaxin
Both repertaxin and placebo were aqueous solutions packaged into identical clear glass Type I ampoule single dose units. The dosing solution for infusion was prepared aseptically at the designated Pharmacy within each center and dispensed as 12.65 mg/mL solution in appropriate size infusion bags. ampoule contained 10 mL of either repertaxin or placebo. An initial 'loading dose' of 9 mg/ml sodium chloride (NaCl) solution was administered over 30 minutes, followed by a maintenance dose lasting 47.5 hours.
Other: Placebo
An initial 'loading dose' of repertaxin was administered over 30 minutes by intravenous infusion followed by a maintenance dose lasting 47.5 hours.The infusion was to start approximately 2 hours prior to the anticipated time of reperfusion and was to continue during the ICU/hospital stay. The study medication was administered as a continuous intravenous infusion into a (high flow) central vein, by an infusion pump adequate to provide reliable infusion rates , as per treatment schedule. Total infusion volume was not to exceed 500 mL/24 hours.
An initial 'loading dose' of placebo was administered over 30 minutes by intravenous infusion followed by a maintenance dose lasting 47.5 hours.The infusion was to start approximately 2 hours prior to the anticipated time of reperfusion and was to continue during the ICU/hospital stay. The placebo was administered as a continuous intravenous infusion into a (high flow) central vein, by an infusion pump adequate to provide reliable infusion rates , as per treatment schedule. Total infusion volume was not to exceed 500 mL/24 hours.
Also known as: Placebo comparator
PaO2/FiO2 Ratio at ICU Admission (Time 0) and 24 Hours
The PaO2/FiO2 ratio was calculated to assess the severity of hypoxemia, or low blood oxygen levels. A low PaO2/FiO2 value has been associated with increased mortality and hospital stay in patients admitted to the intensive care unit (ICU). It was calculated by dividing the partial pressure of oxygen in arterial blood (PaO2) by the fraction of inspired oxygen (FiO2). A normal P/F ratio was typically above 300, and a lower ratio indicates a greater severity of hypoxemia. As the Pa02/Fi02 ratio was dependent on altitude, data were corrected for altitude in the analyses of corrected data. The correction factor is defined as (Pressure at Denver)/(Pressure at sea level) = 633/760 = 0.8329; PaO2 values were corrected as follows: Corrected value = measured value/0.8329
Time frame: At T0 (time of ICU admission) and 24 hours post-ICU admission
PaO2/FiO2 Ratio (ICU Admission Then 24 Hours up to Extubation or up to 72 Hours)
Time profile of oxygenation was a comparison of the sequential measurements of the ratios of arterial PaO2 to inspired oxygen fractions FiO2. Herein repeated measurements analysis of PaO2/FiO2 ratio corrected after ICU admission using a one-sided test excluding missing data.
Time frame: At ICU admission (T0), 24, 48 and 72 hours post-ICU admission
Number of Patients With Different Primary Graft Dysfunction (PGD) Scores (0-3, and Missing Data)
PGD after lung transplantation ranged from mild to severe depending on the level of hypoxaemia and lung injury post-transplant. PGD score was calculated according to the scoring system below: Grade 0 PaO2/FiO2 \>=300 mmHg; no radiographic infiltrates (RI); Grade 1 PaO2/FiO2 \>=300mmHg + RI consistent with pulmonary oedema; Grade 2 200 mmHg \<=PaO2/FiO2 \<=300 mm Hg + RI consistent with pulmonary oedema; Grade 3 PaO2/FiO2 \< 200 mm Hg + RI consistent with pulmonary oedema. The higher the score, the worse the outcome. Any patient with no infiltrate on chest X-rays was automatically Grade 0. If the patient was on nasal cannula for oxygen or FiO2 \<0.3, the patient was graded as 0 or 1, based on chest X-rays. Any patient on extracorporeal membrane oxygenation was Grade 3. Any subject mechanically ventilated with FiO2 greater than 0.5 or requiring nitric oxide beyond 48 hours from the time of transplant was Grade 3.
Time frame: At ICU admission (T0), 24, 48 and 72 hours post-ICU admission
Time to Freedom From Mechanical Ventilation
Time to freedom from mechanical ventilation was defined as "time between admission to the ICU and the initial time of first extubation (breathing off mechanical ventilation without a tube) which was maintained for more than 24 hours". This number was measured in hours and was derived as (date/time of extubation-date/time of ICU admission)/3600. The longer the time, the worst the outcome.Time to freedom from mechanical ventilation, if greater than 1 month (720 hours), was censored to 720 hours. Patients re-transplanted were censored at the date/time of re-transplant. Herein differences in the time to freedom from mechanical ventilation were reported between placebo and repertaxin.
Time frame: At 24, 48, 72 hours post ICU admission
Probability of Death During Intensive Care Unit (ICU) Stay at Different Timepoints
The duration of ICU stay, in term of hours, at different timepoints, in both placebo and repertaxin groups, was measured. The longer the ICU stay, the worse the outcome. mean event probability" (death) and its standard error (SE) at each timepoint.
Time frame: At 24, 48, 72 hours post ICU admission
Number of Patients Dead Within 30 Days Post-transplant
Mortality, defined as any death occurring in the first 30 days post-transplant, regardless of hospital discharge.
Time frame: Up to 30 days post-transplant
Pulmonary Function Tests (FEV1=Forced Expiratory Volume in One Second and FVC=Forced Vital Capacity) at Month 1, 6 and 12 Post-transplant Evaluated According to Estenne et al.(2002).
Forced expiratory volume in 1 second (FEV1) measured the amount/ volume, exhaled by a patient in the first second of the expiration after a full inspiration. Average values in healthy patients aged 20-60 range from 4.5 to 3.5 liters in males and from 3.25 to 2.5 liters in females. Forced vital capacity (FVC) was the volume of air that a patient could exhale with a maximal forced expiration effort after a deep inhaling, simply put, how much air a patient could breathe out by blowing as fast as possible. Average values in healthy patients aged 20-60 range from 5.5 to 4.75 liters in males and from 3.75 to 3.25 liters in females. The lower the values fo both parameters, the worse the outcome.
Time frame: At months 1, 6 and 12 post-transplant
Number of Patients With Different Bronchiolitis Obliterans Syndrome (BOS) Scores (0-3) Assessed at Months 6 and 12 Post-transplant
BOS is defined as an irreversible decline in forced expiratory volume in 1 second (FEV1) of at least 20% from baseline. Spirometric measurements must be made with equipment that conforms to the American Thoracic Society standards for spirometric testing. Here the classification where stage 3 is the worst: BOS 0 FEV1 \>90% of baseline and FEF25-75 \>75% of baseline. BOS 0-p FEV1 \>81% to 90% of baseline and/or FEF25-75 \> 75% of baseline. BOS 1 FEV1 \>66% to 80% of baseline. BOS 2 FEV1 \>51% to 65% of baseline BOS 3 FEV1 \>50% or less of baseline. CRF data are reported.
Time frame: At Months 6 and 12 post-transplant
Number of Patients With at Least One Acute Rejection Episode at Months 1, 6 and 12 Post-transplant
Acute rejection was diagnosed according to Yousem et al. (1996). Histopathologic assessment of transbronchial biopsies first required confirmation of the diagnosis of mild (ACR; A2) using criteria defined in the Working Formulation for Lung Allograft Rejection. Morphological variables assessed included: one or more perivascular infiltrates in the total transbronchial biopsy fragments obtained at one bronchoscopy session, the presence of large or small airway inflammation, endothelialitis, eosinophils, plasma cells, intra-airway and intra-airspace granulation tissue, and alveolar hemosiderosis. The Working Formulation for grading of acute rejection of lung allografts contains five acute rejection grades: A0, none; A1, minimal; A2, mild; A3, moderate; and A4, severe; and is based on the intensity of perivascular mononuclear infiltrates and their extension into alveolar septa.
Time frame: At months 1, 6 and 12 post-transplant
Patient Survival up to 12 Months Post-transplant
Patient survival is derived from the date of ICU admission untile the date of death or study completion/withdrawal. Here this parameter is expressed as the "cumulative number of events (death)" at different timepoints till month 12, per arm.
Time frame: at Months 3, 6, 9 and 12 post-transplant
Number of Patients With at Least One Adverse Events Within the First Month
An AE was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Time frame: to month 1
Number of Patients With at Least One Adverse Events From Month 1 to Month 12
An AE was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Time frame: from month 1 to month 12
A total of 233 subjects were screened, of whom 114 were randomised and 119 were screen failures.
| Milestone | Repertaxin | Placebo |
|---|---|---|
| Started | 55 | 59 |
| Intention to treat population (itt) | 46 | 55 |
| Per protocol population (pp) | 46 | 53 |
| Safety population (saf) | 46 | 55 |
| Completed | 46 | 52 |
| Not completed | 9 | 7 |
| Withdrew: Re-transplant | 0 | 2 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Transplant cancelled | 0 | 4 |
| Withdrew: Drug not delivered | 2 | 0 |
| Withdrew: Other | 4 | 0 |
| Withdrew: Transplant cancelled | 3 | 0 |
The PaO2/FiO2 ratio was calculated to assess the severity of hypoxemia, or low blood oxygen levels. A low PaO2/FiO2 value has been associated with increased mortality and hospital stay in patients admitted to the intensive care unit (ICU). It was calculated by dividing the partial pressure of oxygen in arterial blood (PaO2) by the fraction of inspired oxygen (FiO2). A normal P/F ratio was typically above 300, and a lower ratio indicates a greater severity of hypoxemia. As the Pa02/Fi02 ratio was dependent on altitude, data were corrected for altitude in the analyses of corrected data. The correction factor is defined as (Pressure at Denver)/(Pressure at sea level) = 633/760 = 0.8329; PaO2 values were corrected as follows: Corrected value = measured value/0.8329
| ratio of PaO2/FiO2 | Repertaxin (ITT) | Placebo (ITT) |
|---|---|---|
| ICU Admission (Time 0) | 346.3 ± 125.5 | 337.9 ± 143.0 |
| 24 Hours Post ICU Admission | 320.1 ± 119.5 | 307.3 ± 111.3 |
Time profile of oxygenation was a comparison of the sequential measurements of the ratios of arterial PaO2 to inspired oxygen fractions FiO2. Herein repeated measurements analysis of PaO2/FiO2 ratio corrected after ICU admission using a one-sided test excluding missing data.
| ratio of PaO2/FiO2 | Repertaxin (ITT) | Placebo (ITT) |
|---|---|---|
| ICU Admission (Time 0) | 346.3 ± 125.5 | 337.9 ± 143.0 |
| 24 Hours Post ICU Admission | 320.1 ± 119.5 | 307.3 ± 111.3 |
| 48 Hours Post ICU Admission | 266.1 ± 117.3 | 279.2 ± 151.8 |
| 72 Hours Post ICU Admission | 275.6 ± 88.1 | 233.9 ± 132.0 |
PGD after lung transplantation ranged from mild to severe depending on the level of hypoxaemia and lung injury post-transplant. PGD score was calculated according to the scoring system below: Grade 0 PaO2/FiO2 \>=300 mmHg; no radiographic infiltrates (RI); Grade 1 PaO2/FiO2 \>=300mmHg + RI consistent with pulmonary oedema; Grade 2 200 mmHg \<=PaO2/FiO2 \<=300 mm Hg + RI consistent with pulmonary oedema; Grade 3 PaO2/FiO2 \< 200 mm Hg + RI consistent with pulmonary oedema. The higher the score, the worse the outcome. Any patient with no infiltrate on chest X-rays was automatically Grade 0. If the patient was on nasal cannula for oxygen or FiO2 \<0.3, the patient was graded as 0 or 1, based on chest X-rays. Any patient on extracorporeal membrane oxygenation was Grade 3. Any subject mechanically ventilated with FiO2 greater than 0.5 or requiring nitric oxide beyond 48 hours from the time of transplant was Grade 3.
| Participants | Repertaxin (ITT) | Placebo (ITT) |
|---|---|---|
| ICU Admission (Time 0) - PGD Score Missing | 0 | 1 |
| ICU Admission (Time 0) - PGD Score 0 | 28 | 33 |
| ICU Admission (Time 0) - PGD Score 1 | 9 | 8 |
| ICU Admission (Time 0) - PGD Score 2 | 6 | 4 |
| ICU Admission (Time 0) - PGD Score 3 | 3 | 9 |
| 24 Hours Post ICU Admission - PGD Score Missing | 0 | 1 |
| 24 Hours Post ICU Admission - PGD Score 0 | 22 | 30 |
| 24 Hours Post ICU Admission - PGD Score 1 | 14 | 12 |
| 24 Hours Post ICU Admission - PGD Score 2 | 5 | 6 |
| 24 Hours Post ICU Admission - PGD Score 3 | 5 | 6 |
| 48 Hours Post ICU Admission - PGD Score Missing | 0 | 3 |
| 48 Hours Post ICU Admission - PGD Score 0 | 22 | 24 |
| 48 Hours Post ICU Admission - PGD Score 1 | 15 | 17 |
| 48 Hours Post ICU Admission - PGD Score 2 | 4 | 2 |
| 48 Hours Post ICU Admission - PGD Score 3 | 5 | 9 |
| 72 Hours Post ICU Admission - PGD Score Missing | 1 | 3 |
| 72 Hours Post ICU Admission - PGD Score 0 | 22 | 27 |
| 72 Hours Post ICU Admission - PGD Score 1 | 16 | 17 |
| 72 Hours Post ICU Admission - PGD Score 2 | 3 | 2 |
| 72 Hours Post ICU Admission - PGD Score 3 | 4 | 6 |
Time to freedom from mechanical ventilation was defined as "time between admission to the ICU and the initial time of first extubation (breathing off mechanical ventilation without a tube) which was maintained for more than 24 hours". This number was measured in hours and was derived as (date/time of extubation-date/time of ICU admission)/3600. The longer the time, the worst the outcome.Time to freedom from mechanical ventilation, if greater than 1 month (720 hours), was censored to 720 hours. Patients re-transplanted were censored at the date/time of re-transplant. Herein differences in the time to freedom from mechanical ventilation were reported between placebo and repertaxin.
| hours | Repertaxin (ITT) | Placebo (ITT) |
|---|---|---|
| 24 Hours Post-ICU Admission | 0.5000 ± 0.0737 | 0.4909 ± 0.0674 |
| 48 Hours Post-ICU Admission | 0.6957 ± 0.0678 | 0.7273 ± 0.0601 |
| 72 Hours Post-ICU Admission | 0.7391 ± 0.0647 | 0.8052 ± 0.0541 |
The duration of ICU stay, in term of hours, at different timepoints, in both placebo and repertaxin groups, was measured. The longer the ICU stay, the worse the outcome. mean event probability" (death) and its standard error (SE) at each timepoint.
| event probability | Repertaxin (ITT) | Placebo (ITT) |
|---|---|---|
| At 24 h hours post ICU admission | 0.0000 ± 0.0000 | 0.0364 ± 0.0252 |
| At 48 h hours post ICU admission | 0.3261 ± 0.0691 | 0.2909 ± 0.0612 |
| At 72 h hours post ICU admission | 0.4783 ± 0.0737 | 0.4962 ± 0.0679 |
Mortality, defined as any death occurring in the first 30 days post-transplant, regardless of hospital discharge.
| Participants | Repertaxin (ITT) | Placebo (ITT) |
|---|---|---|
| Number of Patients Dead Within 30 Days Post-transplant | 0 | 1 |
Forced expiratory volume in 1 second (FEV1) measured the amount/ volume, exhaled by a patient in the first second of the expiration after a full inspiration. Average values in healthy patients aged 20-60 range from 4.5 to 3.5 liters in males and from 3.25 to 2.5 liters in females. Forced vital capacity (FVC) was the volume of air that a patient could exhale with a maximal forced expiration effort after a deep inhaling, simply put, how much air a patient could breathe out by blowing as fast as possible. Average values in healthy patients aged 20-60 range from 5.5 to 4.75 liters in males and from 3.75 to 3.25 liters in females. The lower the values fo both parameters, the worse the outcome.
| Litres | Repertaxin (ITT) | Placebo (ITT) |
|---|---|---|
| FEV1 - Month 1 post transplant | 2.20 ± 0.74 | 2.05 ± 0.84 |
| FEV1 - Month 6 post transplant | 2.62 ± 0.95 | 2.34 ± 0.85 |
| FEV1 - Month 12 post transplant | 2.52 ± 1.07 | 2.22 ± 0.95 |
| FVC - Month 1 post transplant | 2.49 ± 0.70 | 2.56 ± 1.01 |
| FVC - Month 6 post transplant | 3.19 ± 0.93 | 3.11 ± 0.99 |
| FVC - Month 12 post transplant | 3.19 ± 1.05 | 3.07 ± 1.10 |
BOS is defined as an irreversible decline in forced expiratory volume in 1 second (FEV1) of at least 20% from baseline. Spirometric measurements must be made with equipment that conforms to the American Thoracic Society standards for spirometric testing. Here the classification where stage 3 is the worst: BOS 0 FEV1 \>90% of baseline and FEF25-75 \>75% of baseline. BOS 0-p FEV1 \>81% to 90% of baseline and/or FEF25-75 \> 75% of baseline. BOS 1 FEV1 \>66% to 80% of baseline. BOS 2 FEV1 \>51% to 65% of baseline BOS 3 FEV1 \>50% or less of baseline. CRF data are reported.
| Participants | Repertaxin (ITT) | Placebo (ITT) |
|---|---|---|
| Month 6 Post Transplant - BOS Missing | 0 | 4 |
| Month 6 Post Transplant - BOS 0 | 45 | 44 |
| Month 6 Post Transplant - BOS 1 | 1 | 3 |
| Month 6 Post Transplant - BOS 2 | 0 | 1 |
| Month 6 Post Transplant - BOS 3 | 0 | 0 |
| Month 12 Post Transplant - Missing | 4 | 7 |
| Month 12 Post Transplant - BOS 0 | 35 | 36 |
| Month 12 Post Transplant - BOS 1 | 1 | 5 |
| Month 12 Post Transplant - BOS 2 | 3 | 2 |
| Month 12 Post Transplant - BOS 3 | 3 | 2 |
Acute rejection was diagnosed according to Yousem et al. (1996). Histopathologic assessment of transbronchial biopsies first required confirmation of the diagnosis of mild (ACR; A2) using criteria defined in the Working Formulation for Lung Allograft Rejection. Morphological variables assessed included: one or more perivascular infiltrates in the total transbronchial biopsy fragments obtained at one bronchoscopy session, the presence of large or small airway inflammation, endothelialitis, eosinophils, plasma cells, intra-airway and intra-airspace granulation tissue, and alveolar hemosiderosis. The Working Formulation for grading of acute rejection of lung allografts contains five acute rejection grades: A0, none; A1, minimal; A2, mild; A3, moderate; and A4, severe; and is based on the intensity of perivascular mononuclear infiltrates and their extension into alveolar septa.
| Participants | Repertaxin (ITT) | Placebo (ITT) |
|---|---|---|
| Month 1 Post transplant | 17 | 19 |
| Month 6 Post Transplant | 35 | 33 |
| Month 12 Post Transplant | 17 | 13 |
Patient survival is derived from the date of ICU admission untile the date of death or study completion/withdrawal. Here this parameter is expressed as the "cumulative number of events (death)" at different timepoints till month 12, per arm.
| number of events | Repertaxin (ITT) | Placebo (ITT) |
|---|---|---|
| 3 Months | 0 | 3 |
| 6 Months | 0 | 5 |
| 9 Months | 0 | 6 |
| 12 Months | 0 | 7 |
An AE was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
| Participants | Repertaxin (SAF) | Placebo (SAF) |
|---|---|---|
| Number (%) of patients reporting at least one TEAE | 46 | 55 |
| Number (%) of patients reporting at least one TEAE leading to discontinuation of study drug | 1 | 0 |
| Number (%) of patients reporting at least one serious TEAE | 14 | 14 |
| Number (%) of patients reporting at least one TEAE leading to death | 0 | 0 |
| Number (%) of patients reporting TEAEs with no relationship to study drug | 19 | 26 |
| Number (%) of patients reporting TEAEs with unlikely relationship to study drug | 18 | 22 |
| Number (%) of patients reporting TEAEs with possible study drug | 9 | 7 |
| Number (%) of patients reporting TEAEs with probable relationship to study drug | 0 | 0 |
| Number (%) of patients reporting TEAEs with highly probable relationship to study drug | 0 | 0 |
| Number (%) of patients reporting Serious TEAEs with no relationship to study drug | 5 | 6 |
| Number (%) of patients reporting Serious TEAEs with unlikely relationship to study drug | 5 | 6 |
| Number (%) of patients reporting Serious TEAEs with possible relationship to study drug | 4 | 2 |
| Number (%) of patients reporting Serious TEAEs with probable relationship to study drug | 0 | 0 |
| Number (%) of patients reporting Serious TEAEs with highly probable relationship to study drug | 0 | 0 |
An AE was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
| participants | Repertaxin (SAF) | Placebo (SAF) |
|---|---|---|
| Number of patients with TEAEs | 46 | 40 |
| Number (%) of patients reporting at least one TEAE | 21 | 20 |
| Number (%) of patients reporting at least one TEAE leading to discontinuation of study drug | 0 | 0 |
| Number (%) of patients reporting at least one serious TEAE | 0 | 0 |
| Number (%) of patients reporting at least one TEAE leading to death | 0 | 0 |
| Number (%) of patients reporting TEAEs with no relationship to study drug | 11 | 9 |
| Number (%) of patients reporting TEAEs with unlikely relationship to study drug | 9 | 8 |
| Number (%) of patients reporting TEAEs with possible relationship to study drug | 1 | 3 |
| Number (%) of patients reporting TEAEs with probable relationship to study drug | 0 | 0 |
| Number (%) of patients reporting TEAEs with highly probable relationship to study drug | 0 | 0 |
Collected over The specific period of time over which adverse events data were collected was from the start of infusion to Month 12 visit. Note that in Placebo population the number of subject was 52 instead of 55 in the period from Month 1 to Month 12.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Repertaxin (SAF) | 1/46 (2.2%) | 14/46 (30.4%) | 46/46 (100%) |
| Placebo (SAF) | 6/55 (10.9%) | 14/55 (25.5%) | 55/55 (100%) |
| Event | Repertaxin (SAF) | Placebo (SAF) |
|---|---|---|
| CoagulopathyBlood and lymphatic system disorders | 3/46 | 2/55 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 3/46 | 0/55 |
| Atrial fibrillationCardiac disorders | 1/46 | 3/55 |
| HaemorrageVascular disorders | 2/46 | 3/55 |
| HypotensionVascular disorders | 0/46 | 3/55 |
| Lung transplant rejectionImmune system disorders | 1/46 | 2/55 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/46 | 2/55 |
| Pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 0/46 | 2/55 |
| Reperfusion injuryVascular disorders | 0/46 | 2/55 |
| Cardiac arrestCardiac disorders | 1/46 | 0/55 |
| Event | Repertaxin (SAF) | Placebo (SAF) |
|---|---|---|
| Incision site complicationInjury, poisoning and procedural complications | 35/46 | 33/55 |
| ConstipationGastrointestinal disorders | 28/46 | 21/55 |
| NauseaGastrointestinal disorders | 20/46 | 19/55 |
| HyperglycaemiaMetabolism and nutrition disorders | 20/46 | 23/55 |
| HypotensionVascular disorders | 14/46 | 14/55 |
| HypomagnesaemiaMetabolism and nutrition disorders | 12/46 | 16/55 |
| AnaemiaBlood and lymphatic system disorders | 13/46 | 5/55 |
| HypokalaemiaMetabolism and nutrition disorders | 12/46 | 15/55 |
| HypervolaemiaMetabolism and nutrition disorders | 5/46 | 14/55 |
| InsomniaPsychiatric disorders | 11/46 | 13/55 |
The safety population (SAF) consisted of all patients who received any study medication and was based on the treatment actually received.
| Age, Categorical(Participants) | Repertaxin (SAF) | Placebo (SAF) | Total |
|---|---|---|---|
| <=18 years | 0 | 1 | 1 |
| Between 18 and 65 years | 46 | 50 | 96 |
| >=65 years | 0 | 4 | 4 |
| Age, Continuous(years) | Repertaxin (SAF) | Placebo (SAF) | Total |
|---|---|---|---|
| Mean | 46.2 ± 13.5 | 50.9 ± 12.2 | 48.7 ± 13.0 |
| Sex: Female, Male(Participants) | Repertaxin (SAF) | Placebo (SAF) | Total |
|---|---|---|---|
| Female | 23 | 27 | 50 |
| Male | 23 | 28 | 51 |
| Race (NIH/OMB)(Participants) | Repertaxin (SAF) | Placebo (SAF) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 45 | 55 | 100 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Repertaxin (SAF) | Placebo (SAF) | Total |
|---|---|---|---|
| Canada | 16 | 17 | 33 |
| United States | 30 | 38 | 68 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2005 to primary completion in Sep 2006, 16 months.
Results were first posted in Dec 2024, 18 years 2 months after primary completion.
Of 18 phase 2 interventional studies under Reperfusion Injury, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's 16 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Reparixin